Nanomedicine has shown great potential in the treatment of kidney diseases through targeted drug delivery. Nanoparticles, liposomes, micelles, and nanogels are promising nanocarriers that can deliver drugs to specific kidney cells, improving therapeutic efficacy while minimizing side effects. These nanocarriers have unique properties such as high biocompatibility, controlled drug release, and the ability to target specific kidney cells. The kidneys have a complex structure with various cell types, making them a potential target for nanomedicine. Nanoparticles can pass through the glomerular filtration barrier and reach the target cells, while active targeting strategies use specific ligands to enhance drug delivery to kidney tissues. The size, surface charge, and shape of nanoparticles influence their ability to pass through the filtration barrier and reach the target cells. Additionally, nanogels, liposomes, and micelles have been studied for their potential in delivering drugs to the kidneys, with each having unique advantages in terms of drug loading, release, and targeting. The application of nanomedicine in kidney disease treatment is still in its early stages, and further research is needed to ensure the safety and efficacy of these nanocarriers in clinical settings. Overall, nanomedicine offers a promising approach for the targeted treatment of kidney diseases with improved therapeutic outcomes.Nanomedicine has shown great potential in the treatment of kidney diseases through targeted drug delivery. Nanoparticles, liposomes, micelles, and nanogels are promising nanocarriers that can deliver drugs to specific kidney cells, improving therapeutic efficacy while minimizing side effects. These nanocarriers have unique properties such as high biocompatibility, controlled drug release, and the ability to target specific kidney cells. The kidneys have a complex structure with various cell types, making them a potential target for nanomedicine. Nanoparticles can pass through the glomerular filtration barrier and reach the target cells, while active targeting strategies use specific ligands to enhance drug delivery to kidney tissues. The size, surface charge, and shape of nanoparticles influence their ability to pass through the filtration barrier and reach the target cells. Additionally, nanogels, liposomes, and micelles have been studied for their potential in delivering drugs to the kidneys, with each having unique advantages in terms of drug loading, release, and targeting. The application of nanomedicine in kidney disease treatment is still in its early stages, and further research is needed to ensure the safety and efficacy of these nanocarriers in clinical settings. Overall, nanomedicine offers a promising approach for the targeted treatment of kidney diseases with improved therapeutic outcomes.